The results of this post hoc analysis support the hypothesis that benralizumab reduces the risk for recurrent COPD exacerbations within the vulnerable 30-to-90–day period in the previously identified responder population.
The use of biologic therapies, including monoclonal antibodies, has revolutionized the treatment of many human diseases.
En la XXXV edición de las Jornadas Técnicas del Institut Guttmann expertos en neurorrehabilitación, en metodología XPA, en humanización y en gestión aportaron conocimientos, ideas y buenas prácticas para humanizar la gestión y la atención sanitaria en las organizaciones asistenciales.
In this expert interview, MeiLan K Han and Alvar Agustí discuss the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 executive report, which proposes a new definition for COPD and covers the latest updates in its diagnosis, management, and prevention.
Taking place on 5 July, this ERS Vision Live panel discussion will focus on new concepts in chronic obstructive pulmonary disease (COPD).
The term GETomics has been recently proposed to illustrate that human health and disease are actually the final outcome of many dynamic, interacting and cumulative gene environment interactions that occur through the lifetime of the individual.
The Global Burden of Disease Study 2017 identified that a country’s sociodemographic index was a key factor affecting mortality and loss of health from respiratory diseases.
COPD is the elephant in the room for many patients with CVDs.
Chronic Obstructive Pulmonary Disease (COPD) is the third cause of death worldwide. While tobacco smoking is a key risk factor, COPD also occurs in never-smokers (NS).
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.
